Scienture, LLC, a wholly owned subsidiary of Scienture Holdings, Inc. (NASDAQ: SCNX) Announces Issuance of a New Patent Covering its first product SCN-102 (Losartan Potassium Oral Suspension, 10mg/mL) through 2041
Portfolio Pulse from
Scienture Holdings, Inc. (NASDAQ: SCNX) announced that its subsidiary, Scienture, LLC, has been granted a new patent for its product SCN-102, extending its patent coverage through 2041. This strengthens the company's intellectual property position.
December 10, 2024 | 1:30 pm
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
Scienture Holdings, Inc. has received a new patent for its product SCN-102, extending its protection until 2041. This development enhances the company's intellectual property portfolio, potentially increasing its market competitiveness.
The issuance of a new patent for SCN-102 extends its market exclusivity, which is likely to enhance Scienture's competitive edge and potentially increase future revenues. This is a positive development for SCNX, as it secures long-term protection for one of its products.
CONFIDENCE 95
IMPORTANCE 80
RELEVANCE 90